← boardnext 2027-06-30
ELOX
Eloxx Pharmaceuticals, Inc.distress 6/10 · elevated risk$12.13-3%today-17% from 52w high
Lead: Alport Syndrome
Revenue
pre-revenue
Liquidity
$6M
Runway
0.3 yrs
Shares 1y
+49%
Price & events
+10.2% over 6M
CatalystRating changeDilutionFinancingdashed = today
-2.7%
1D
+0.9%
1W
-0.7%
1M
—
3M
—
6M
—
1Y
—
2Y
—
5Y
+10.2%
All
Overview
- Market Cap
- $91.87M
- Enterprise Value
- $85.51M
- Volume
- 1.20K
- 52 Week Range
- $10.95 – $14.70
- Total Shares
- 7.57M
- Float Shares
- 310.61K
- Short %
- 0.25%
- % Held by Insiders
- 26.28%
- % Held by Institutions
- 38.92%
- RVOL
- 0.02x
- Beta
- -165013.73
Pipeline stages · 1 programs
Exaluren
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 1 trials · 1 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2027-06-30 Estimated 50% readout ~2027-08-14 | Phase 2 | Exaluren | Alport Syndrome, X-Linked, Alport Syndrome, Autosomal Recessive | — | not yet recruiting |
Catalyst news & presentations · 0
- No catalyst news yet.
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $43 (+254% upside) · 1 analysts
- 2026-07-20GuggenheimBuy
Recent news
- 2026-07-23ELOX stock holds on report context and clinical milestones - Ad-hoc-news.de
- 2026-07-23Eloxx Pharmaceuticals (ELOX) Q4 2025 earnings summary - Quartr
- 2026-07-23Eloxx Pharmaceuticals (ELOX) Q1 2026 earnings summary - Quartr
- 2026-07-20Guggenheim Initiates Eloxx Pharmaceuticals at Buy With $43 Price Target - marketscreener.com
- 2026-07-20Eloxx Pharmaceuticals initiated with a Buy at Guggenheim - TipRanks
- 2026-07-14ELOX Price Today: Eloxx Pharmaceuticals, Inc. Stock Price, Quote & Chart - mexc.co
- 2026-07-09ELOX stock trades on Nasdaq as small-cap biotech focuses on cystic fibrosis therapy - Ad-hoc-news.de
- 2026-07-06Price to sales forward of Eloxx Pharmaceuticals, Inc. – BOATS:ELOX - TradingView
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.